ERxin

Drug Profile

ERxin

Latest Information Update: 27 May 2009

Price : $50

At a glance

  • Originator Repros Therapeutics
  • Class Imidazoles
  • Mechanism of Action Alpha adrenergic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Erectile dysfunction

Most Recent Events

  • 01 Oct 2002 Suspended - Phase-II for Erectile dysfunction in USA (Intracavernous)
  • 06 Jul 2001 Clinical data have been added to the Men's Health pharmacodynamics section
  • 05 Jul 2001 Phase-II clinical trials for Erectile dysfunction in Mexico (Intracavernous)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top